Peer-reviewedCC BY-NC-NDTranslational Lung Cancer Research
Prognostic impact of immune-related adverse events in non-completers of durvalumab consolidation therapy for non-small cell lung cancer: a single-center retrospective cohort study
Related
- Real-World Clinical Outcomes and Treatment Patterns in Patients with Unresectable Stage III NSCLC Treated with CCRT With or Without Durvalumab as Consolidation Therapy: A Retrospective Cohort Study
- InDuRanS: neoadjuvant immunochemotherapy followed by surgery or definitive chemoradiotherapy and consolidation durvalumab in resectable and borderline resectable stage IIB-IIIA/B non-small-cell lung cancer.
- Efficacy of Sorafenib Combined with Venetoclax and Azacitidine in Newly Diagnosed FLT3-ITD-Mutant Acute Myeloid Leukemia: Remission Efficacy and Prognostic Influence of Post-Remission Consolidation Therapy
- Prognostic factors in thyroid cancer with lung-only metastasis: SEER-based retrospective study
- Treatment patterns and prognostic factors of radiation-associated esophageal fistula in patients with esophageal squamous cell carcinoma: a retrospective cohort study
BibTeX
@article{anon2026prognostic,
title = {{Prognostic impact of immune-related adverse events in non-completers of durvalumab consolidation therapy for non-small cell lung cancer: a single-center retrospective cohort study}},
journal = {Translational Lung Cancer Research},
year = {2026},
month = aug,
url = {https://europepmc.org/article/PMC/PMC13657896},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Prognostic impact of immune-related adverse events in non-completers of durvalumab consolidation therapy for non-small cell lung cancer: a single-center retrospective cohort study
PY - 2026
DA - 2026/08/17
JO - Translational Lung Cancer Research
UR - https://europepmc.org/article/PMC/PMC13657896
SN - 2218-6751
ER -